Literature DB >> 23041476

Plasma membrane calcium ATPases and related disorders.

Marta Giacomello1, Agnese De Mario, Chiara Scarlatti, Simona Primerano, Ernesto Carafoli.   

Abstract

The plasma membrane Ca(2+) ATPases (PMCA pumps) cooperate with other transport systems in the plasma membrane and in the organelles in the regulation of cell Ca(2+). They have high Ca(2+) affinity and are thus the fine tuners of cytosolic Ca(2+). They belong to the superfamily of P-type ATPases: their four basic isoforms share the essential properties of the reaction cycle and the general membrane topography motif of 10 transmembrane domains and three large cytosolic units. However they also differ in other important properties, e.g., tissue distribution and regulatory mechanisms. Their chief regulator is calmodulin, that removes their C-terminal cytosolic tail from autoinhibitory binding sites next to the active site of the pump, restoring activity. The number of pump isoforms is increased to over 30 by alternative splicing of the transcripts at a N-terminal site (site A) and at site C within the C-terminal calmodulin binding domain: the splice variants are tissue specific and developmentally regulated. The importance of PMCAs in the maintenance of cellular Ca(2+) homeostasis is underlined by the disease phenotypes, genetic or acquired, caused by their malfunction. Non-genetic PMCA deficiencies have long been considered possible causative factors in disease conditions as important as cancer, hypertension, or neurodegeneration. Those of genetic origin are better characterized: some have now been discovered in humans as well. They concern all four PMCA isoforms, and range from cardiac dysfunctions, to deafness, to hypertension, to cerebellar ataxia.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23041476     DOI: 10.1016/j.biocel.2012.09.016

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  8 in total

Review 1.  Plasma membrane calcium ATPases as novel candidates for therapeutic agent development.

Authors:  Emanuel E Strehler
Journal:  J Pharm Pharm Sci       Date:  2013       Impact factor: 2.327

2.  PMCA4 (ATP2B4) mutation in familial spastic paraplegia causes delay in intracellular calcium extrusion.

Authors:  Philip Wing-Lok Ho; Shirley Yin-Yu Pang; Miaoxin Li; Zero Ho-Man Tse; Michelle Hiu-Wai Kung; Pak-Chung Sham; Shu-Leong Ho
Journal:  Brain Behav       Date:  2015-02-16       Impact factor: 2.708

3.  Robust concentration and frequency control in oscillatory homeostats.

Authors:  Kristian Thorsen; Oleg Agafonov; Christina H Selstø; Ingunn W Jolma; Xiao Y Ni; Tormod Drengstig; Peter Ruoff
Journal:  PLoS One       Date:  2014-09-19       Impact factor: 3.240

4.  Multiple Calcium Export Exchangers and Pumps Are a Prominent Feature of Enamel Organ Cells.

Authors:  Sarah Y T Robertson; Xin Wen; Kaifeng Yin; Junjun Chen; Charles E Smith; Michael L Paine
Journal:  Front Physiol       Date:  2017-05-23       Impact factor: 4.566

5.  A complex of Neuroplastin and Plasma Membrane Ca2+ ATPase controls T cell activation.

Authors:  Mark Korthals; Kristina Langnaese; Karl-Heinz Smalla; Thilo Kähne; Rodrigo Herrera-Molina; Juliane Handschuh; Anne-Christin Lehmann; Dejan Mamula; Michael Naumann; Constanze Seidenbecher; Werner Zuschratter; Kerry Tedford; Eckart D Gundelfinger; Dirk Montag; Klaus-Dieter Fischer; Ulrich Thomas
Journal:  Sci Rep       Date:  2017-08-21       Impact factor: 4.379

6.  Pathological pain processing in mouse models of multiple sclerosis and spinal cord injury: contribution of plasma membrane calcium ATPase 2 (PMCA2).

Authors:  Ersilia Mirabelli; Li Ni; Lun Li; Cigdem Acioglu; Robert F Heary; Stella Elkabes
Journal:  J Neuroinflammation       Date:  2019-11-08       Impact factor: 8.322

7.  Mapping genes for calcium signaling and their associated human genetic disorders.

Authors:  Matthias Hörtenhuber; Enrique M Toledo; Erik Smedler; Ernest Arenas; Seth Malmersjö; Lauri Louhivuori; Per Uhlén
Journal:  Bioinformatics       Date:  2017-08-15       Impact factor: 6.937

8.  Repurposing the FDA-approved anticancer agent ponatinib as a fluconazole potentiator by suppression of multidrug efflux and Pma1 expression in a broad spectrum of yeast species.

Authors:  Lin Liu; Tong Jiang; Jia Zhou; Yikun Mei; Jinyang Li; Jingcong Tan; Luqi Wei; Jingquan Li; Yibing Peng; Changbin Chen; Ning-Ning Liu; Hui Wang
Journal:  Microb Biotechnol       Date:  2021-05-06       Impact factor: 5.813

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.